Literature DB >> 18265995

Treating common problems of the nose and throat in pregnancy: what is safe?

Petros V Vlastarakos1, Leonidas Manolopoulos, Eleftherios Ferekidis, Aris Antsaklis, Thomas P Nikolopoulos.   

Abstract

Although all kinds of medications should be avoided during pregnancy, the majority of pregnant women receive at least one drug and 6% of them during the high-risk period of the first trimester. The aim of the present paper is to discuss the appropriate management of rhinologic and laryngeal conditions that may be encountered during pregnancy. A literature review from Medline and database sources was carried out. Related books and written guidelines were also included. Controlled clinical trials, prospective and retrospective studies, case-control studies, laboratory studies, clinical and systematic reviews, metanalyses, and case reports were analysed. The following drugs are considered relatively safe: beta-lactam antibiotics (with dose adjustment), macrolides (although the use of erythromycin and clarithromycin carries a certain risk), clindamycin, metronidazole (better avoided in the first trimester), amphotericin-B (especially in immunocompromised situations during the second and third trimester) and acyclovir. First-line antituberculous agents isoniazid, ethambutol, pyrazinamide, and ciprofloxacine in drug-resistant tuberculosis can be also used. Non-selective NSAIDs (until the 32nd week), nasal decongestants (with caution and up to 7 days), intranasal corticosteroids, with budesonide as the treatment of choice, second generation antihistamines (cetirizine in the third trimester, or loratadine in the second and third trimester), H2 receptor antagonists (except nizatidine) and proton pump inhibitors (except omeprazole) can be used to relieve patients from the related symptoms. In cases of emergencies, epinephrine, prednisone, prednisolone, methylprednisolone, dimetindene and nebulised b(2) agonists can be used with extreme caution. By contrast, selective COX-2 inhibitors and BCG vaccination are contraindicated in pregnancy. When prescribing to a pregnant woman, the safety of the materno-foetal unit is considered paramount. Although medications are potentially hazardous, misconceptions and suboptimal treatment of the mother might be more harmful to the unborn child. Knowledge update is necessary to avoid unjustified hesitations and provide appropriate counselling and treatment for pregnant women.

Entities:  

Mesh:

Year:  2008        PMID: 18265995     DOI: 10.1007/s00405-008-0601-4

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  109 in total

1.  The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI).

Authors: 
Journal:  Ann Allergy Asthma Immunol       Date:  2000-05       Impact factor: 6.347

Review 2.  [Is there a future for COX-2 inhibitors?].

Authors:  Yair Yodfat
Journal:  Harefuah       Date:  2004-11

Review 3.  The penicillins: a review and update.

Authors:  Elissa Lane Miller
Journal:  J Midwifery Womens Health       Date:  2002 Nov-Dec       Impact factor: 2.388

4.  A population-based case-control teratologic study of oral erythromycin treatment during pregnancy.

Authors:  A E Czeizel; M Rockenbauer; H T Sørensen; J Olsen
Journal:  Reprod Toxicol       Date:  1999 Nov-Dec       Impact factor: 3.143

Review 5.  Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review.

Authors:  Cameron Gilbert; Paolo Mazzotta; Ronen Loebstein; Gideon Koren
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Teratology of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Early Hum Dev       Date:  1987-03       Impact factor: 2.079

7.  Gastroesophageal Reflux Disease in Pregnancy.

Authors:  Mohan Charan; Philip O. Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2001-02

8.  Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.

Authors:  Shekoufeh Nikfar; Mohammad Abdollahi; Myla E Moretti; Laura A Magee; Gideon Koren
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

Review 9.  A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy.

Authors:  Vivian S W Chan
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  [Acyclovir and pregnancy: current aspects].

Authors:  J Haddad; J Messer; D Willard; J Ritter
Journal:  J Gynecol Obstet Biol Reprod (Paris)       Date:  1989
View more
  6 in total

1.  Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital.

Authors:  Jingchao Yan; Jianwen Shen; Ying Li; Fengmin Tang; Nianzu Chen
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-15       Impact factor: 2.503

Review 2.  Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions.

Authors:  Amalia Leceta; Aintzane García; Ander Sologuren; Cristina Campo
Journal:  Drugs Context       Date:  2021-08-10

Review 3.  Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department.

Authors:  Amalia Leceta; Ander Sologuren; Román Valiente; Cristina Campo; Luis Labeaga
Journal:  Drugs Context       Date:  2017-02-03

Review 4.  Diagnosis and treatment of HIV-associated manifestations in otolaryngology.

Authors:  Emily Iacovou; Petros V Vlastarakos; George Papacharalampous; George Kampessis; Thomas P Nikolopoulos
Journal:  Infect Dis Rep       Date:  2012-01-02

5.  Healthcare utilisation by pregnant patients with asthma in South Korea: a cohort study using nationwide claims data.

Authors:  Chang-Hoon Lee; Jimin Kim; Eun Jin Jang; Yun Jung Kim; Seongmi Choi; Joon-Ho Lee; Deog Kyeom Kim; Jae-Joon Yim; Ho Il Yoon
Journal:  BMJ Open       Date:  2015-11-06       Impact factor: 2.692

6.  Inhaled Corticosteroids Use Is Not Associated With an Increased Risk of Pregnancy-Induced Hypertension and Gestational Diabetes Mellitus: Two Nested Case-Control Studies.

Authors:  Chang-Hoon Lee; Jimin Kim; Eun Jin Jang; Joon-Ho Lee; Yun Jung Kim; Seongmi Choi; Deog Kyeom Kim; Jae-Joon Yim; Ho Il Yoon
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.